Research ExplorerPublicationsOncological outcomes of salvage radical prostatectomy for re...

Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: A multicenter retrospective study

Standard

Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: A multicenter retrospective study. / Marra, Giancarlo; Karnes, Robert Jeffrey; Calleris, Giorgio; Oderda, Marco; Alessio, Paolo; Palazzetti, Anna; Battaglia, Antonino; Pisano, Francesca; Munegato, Stefania; Munoz, Fernando; Filippini, Claudia; Ricardi, Umberto; Linares, Estefania; Sanchez-Salas, Rafael; Goonewardene, Sanchia; Dasgupta, Prokar; Challacombe, Ben; Popert, Rick; Cahill, Declan; Gillatt, David; Persad, Raj; Palou, Juan; Joniau, Steven; Smelzo, Salvatore; Piechaud, Thierry; Taille, Alexandre De La; Roupret, Morgan; Albisinni, Simone; van Velthoven, Roland; Morlacco, Alessandro; Vidit, Sharma; Gandaglia, Giorgio; Mottrie, Alexander; Smith, Joseph; Joshi, Shreyas; Fiscus, Gabriel; Berger, Andre; Aron, Monish; Abreu, Andre; Gill, Inderbir S; Van Der Poel, Henk; Tilki, Derya; Murphy, Declan; Lawrentschuk, Nathan; Davis, John; Gontero, Paolo.

In: UROL ONCOL-SEMIN ORI, Vol. 39, No. 5, 05.2021, p. 296.e21-296.e29.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Marra, G, Karnes, RJ, Calleris, G, Oderda, M, Alessio, P, Palazzetti, A, Battaglia, A, Pisano, F, Munegato, S, Munoz, F, Filippini, C, Ricardi, U, Linares, E, Sanchez-Salas, R, Goonewardene, S, Dasgupta, P, Challacombe, B, Popert, R, Cahill, D, Gillatt, D, Persad, R, Palou, J, Joniau, S, Smelzo, S, Piechaud, T, Taille, ADL, Roupret, M, Albisinni, S, van Velthoven, R, Morlacco, A, Vidit, S, Gandaglia, G, Mottrie, A, Smith, J, Joshi, S, Fiscus, G, Berger, A, Aron, M, Abreu, A, Gill, IS, Van Der Poel, H, Tilki, D, Murphy, D, Lawrentschuk, N, Davis, J & Gontero, P 2021, 'Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: A multicenter retrospective study', UROL ONCOL-SEMIN ORI, vol. 39, no. 5, pp. 296.e21-296.e29. https://doi.org/10.1016/j.urolonc.2020.11.002

APA

Marra, G., Karnes, R. J., Calleris, G., Oderda, M., Alessio, P., Palazzetti, A., Battaglia, A., Pisano, F., Munegato, S., Munoz, F., Filippini, C., Ricardi, U., Linares, E., Sanchez-Salas, R., Goonewardene, S., Dasgupta, P., Challacombe, B., Popert, R., Cahill, D., ... Gontero, P. (2021). Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: A multicenter retrospective study. UROL ONCOL-SEMIN ORI, 39(5), 296.e21-296.e29. https://doi.org/10.1016/j.urolonc.2020.11.002

Vancouver

Marra G, Karnes RJ, Calleris G, Oderda M, Alessio P, Palazzetti A et al. Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: A multicenter retrospective study. UROL ONCOL-SEMIN ORI. 2021 May;39(5):296.e21-296.e29. https://doi.org/10.1016/j.urolonc.2020.11.002

Bibtex

@article{85d4a5c537704c9698d676716246bcf2,
title = "Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: A multicenter retrospective study",
abstract = "BACKGROUND: Salvage radical prostatectomy (sRP) historically yields poor functional outcomes and high complication rates. However, recent reports on robotic sRP show improved results. Our objectives were to evaluate sRP oncological outcomes and predictors of positive margins and biochemical recurrence (BCR).METHODS: We retrospectively collected data of sRP for recurrent prostate cancer after local nonsurgical treatment at 18 tertiary referral centers in United States, Australia and Europe, from 2000 to 2016. SM and BCR were evaluated in a univariate and multivariable analysis. Overall and cancer-specific survival were also assessed.RESULTS: We included 414 cases, 63.5% of them performed after radiotherapy. Before sRP the majority of patients had biopsy Gleason score (GS) ≤7 (55.5%) and imaging negative or with prostatic bed involvement only (93.3%). Final pathology showed aggressive histology in 39.7% (GS ≥9 27.6%), with 52.9% having ≥pT3 disease and 16% pN+. SM was positive in 29.7%. Five years BCR-Free, cancer-specific survival and OS were 56.7%, 97.7% and 92.1%, respectively. On multivariable analysis pathological T (pT3a odds ratio [OR] 2.939, 95% confidence interval [CI] 1.469-5.879; ≥pT3b OR 2.428-95% CI 1.333-4.423) and N stage (pN1 OR 2.871, 95% CI 1.503-5.897) were independent predictors of positive margins. Pathological T stage ≥T3b (OR 2.348 95% CI 1.338-4.117) and GS (up to OR 7.183, 95% CI 1.906-27.068 for GS >8) were independent predictors for BCR. Limitations include the retrospective nature of the study and limited follow-up.CONCLUSIONS: In a contemporary series, sRP showed promising oncological control in the medium term despite aggressive pathological features. BCR risk increased in case of locally advanced disease and higher GS. Future studies are needed to confirm our findings.",
keywords = "Aged, Humans, Male, Margins of Excision, Middle Aged, Neoplasm Recurrence, Local/surgery, Prostatectomy/methods, Prostatic Neoplasms/pathology, Retrospective Studies, Salvage Therapy, Treatment Outcome",
author = "Giancarlo Marra and Karnes, {Robert Jeffrey} and Giorgio Calleris and Marco Oderda and Paolo Alessio and Anna Palazzetti and Antonino Battaglia and Francesca Pisano and Stefania Munegato and Fernando Munoz and Claudia Filippini and Umberto Ricardi and Estefania Linares and Rafael Sanchez-Salas and Sanchia Goonewardene and Prokar Dasgupta and Ben Challacombe and Rick Popert and Declan Cahill and David Gillatt and Raj Persad and Juan Palou and Steven Joniau and Salvatore Smelzo and Thierry Piechaud and Taille, {Alexandre De La} and Morgan Roupret and Simone Albisinni and {van Velthoven}, Roland and Alessandro Morlacco and Sharma Vidit and Giorgio Gandaglia and Alexander Mottrie and Joseph Smith and Shreyas Joshi and Gabriel Fiscus and Andre Berger and Monish Aron and Andre Abreu and Gill, {Inderbir S} and {Van Der Poel}, Henk and Derya Tilki and Declan Murphy and Nathan Lawrentschuk and John Davis and Paolo Gontero",
note = "Copyright {\textcopyright} 2020. Published by Elsevier Inc.",
year = "2021",
month = may,
doi = "10.1016/j.urolonc.2020.11.002",
language = "English",
volume = "39",
pages = "296.e21--296.e29",
journal = "UROL ONCOL-SEMIN ORI",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "5",

}

RIS

TY - JOUR

T1 - Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: A multicenter retrospective study

AU - Marra, Giancarlo

AU - Karnes, Robert Jeffrey

AU - Calleris, Giorgio

AU - Oderda, Marco

AU - Alessio, Paolo

AU - Palazzetti, Anna

AU - Battaglia, Antonino

AU - Pisano, Francesca

AU - Munegato, Stefania

AU - Munoz, Fernando

AU - Filippini, Claudia

AU - Ricardi, Umberto

AU - Linares, Estefania

AU - Sanchez-Salas, Rafael

AU - Goonewardene, Sanchia

AU - Dasgupta, Prokar

AU - Challacombe, Ben

AU - Popert, Rick

AU - Cahill, Declan

AU - Gillatt, David

AU - Persad, Raj

AU - Palou, Juan

AU - Joniau, Steven

AU - Smelzo, Salvatore

AU - Piechaud, Thierry

AU - Taille, Alexandre De La

AU - Roupret, Morgan

AU - Albisinni, Simone

AU - van Velthoven, Roland

AU - Morlacco, Alessandro

AU - Vidit, Sharma

AU - Gandaglia, Giorgio

AU - Mottrie, Alexander

AU - Smith, Joseph

AU - Joshi, Shreyas

AU - Fiscus, Gabriel

AU - Berger, Andre

AU - Aron, Monish

AU - Abreu, Andre

AU - Gill, Inderbir S

AU - Van Der Poel, Henk

AU - Tilki, Derya

AU - Murphy, Declan

AU - Lawrentschuk, Nathan

AU - Davis, John

AU - Gontero, Paolo

N1 - Copyright © 2020. Published by Elsevier Inc.

PY - 2021/5

Y1 - 2021/5

N2 - BACKGROUND: Salvage radical prostatectomy (sRP) historically yields poor functional outcomes and high complication rates. However, recent reports on robotic sRP show improved results. Our objectives were to evaluate sRP oncological outcomes and predictors of positive margins and biochemical recurrence (BCR).METHODS: We retrospectively collected data of sRP for recurrent prostate cancer after local nonsurgical treatment at 18 tertiary referral centers in United States, Australia and Europe, from 2000 to 2016. SM and BCR were evaluated in a univariate and multivariable analysis. Overall and cancer-specific survival were also assessed.RESULTS: We included 414 cases, 63.5% of them performed after radiotherapy. Before sRP the majority of patients had biopsy Gleason score (GS) ≤7 (55.5%) and imaging negative or with prostatic bed involvement only (93.3%). Final pathology showed aggressive histology in 39.7% (GS ≥9 27.6%), with 52.9% having ≥pT3 disease and 16% pN+. SM was positive in 29.7%. Five years BCR-Free, cancer-specific survival and OS were 56.7%, 97.7% and 92.1%, respectively. On multivariable analysis pathological T (pT3a odds ratio [OR] 2.939, 95% confidence interval [CI] 1.469-5.879; ≥pT3b OR 2.428-95% CI 1.333-4.423) and N stage (pN1 OR 2.871, 95% CI 1.503-5.897) were independent predictors of positive margins. Pathological T stage ≥T3b (OR 2.348 95% CI 1.338-4.117) and GS (up to OR 7.183, 95% CI 1.906-27.068 for GS >8) were independent predictors for BCR. Limitations include the retrospective nature of the study and limited follow-up.CONCLUSIONS: In a contemporary series, sRP showed promising oncological control in the medium term despite aggressive pathological features. BCR risk increased in case of locally advanced disease and higher GS. Future studies are needed to confirm our findings.

AB - BACKGROUND: Salvage radical prostatectomy (sRP) historically yields poor functional outcomes and high complication rates. However, recent reports on robotic sRP show improved results. Our objectives were to evaluate sRP oncological outcomes and predictors of positive margins and biochemical recurrence (BCR).METHODS: We retrospectively collected data of sRP for recurrent prostate cancer after local nonsurgical treatment at 18 tertiary referral centers in United States, Australia and Europe, from 2000 to 2016. SM and BCR were evaluated in a univariate and multivariable analysis. Overall and cancer-specific survival were also assessed.RESULTS: We included 414 cases, 63.5% of them performed after radiotherapy. Before sRP the majority of patients had biopsy Gleason score (GS) ≤7 (55.5%) and imaging negative or with prostatic bed involvement only (93.3%). Final pathology showed aggressive histology in 39.7% (GS ≥9 27.6%), with 52.9% having ≥pT3 disease and 16% pN+. SM was positive in 29.7%. Five years BCR-Free, cancer-specific survival and OS were 56.7%, 97.7% and 92.1%, respectively. On multivariable analysis pathological T (pT3a odds ratio [OR] 2.939, 95% confidence interval [CI] 1.469-5.879; ≥pT3b OR 2.428-95% CI 1.333-4.423) and N stage (pN1 OR 2.871, 95% CI 1.503-5.897) were independent predictors of positive margins. Pathological T stage ≥T3b (OR 2.348 95% CI 1.338-4.117) and GS (up to OR 7.183, 95% CI 1.906-27.068 for GS >8) were independent predictors for BCR. Limitations include the retrospective nature of the study and limited follow-up.CONCLUSIONS: In a contemporary series, sRP showed promising oncological control in the medium term despite aggressive pathological features. BCR risk increased in case of locally advanced disease and higher GS. Future studies are needed to confirm our findings.

KW - Aged

KW - Humans

KW - Male

KW - Margins of Excision

KW - Middle Aged

KW - Neoplasm Recurrence, Local/surgery

KW - Prostatectomy/methods

KW - Prostatic Neoplasms/pathology

KW - Retrospective Studies

KW - Salvage Therapy

KW - Treatment Outcome

U2 - 10.1016/j.urolonc.2020.11.002

DO - 10.1016/j.urolonc.2020.11.002

M3 - SCORING: Journal article

C2 - 33436329

VL - 39

SP - 296.e21-296.e29

JO - UROL ONCOL-SEMIN ORI

JF - UROL ONCOL-SEMIN ORI

SN - 1078-1439

IS - 5

ER -